Vildagliptin Sr 100 Mg + Dapagliflozin 10 Mg

The dosage of Vildagliptin SR 100 mg + Dapagliflozin 10 mg may vary depending on individual patient factors and glycemic control goals. It is typically taken orally once daily with or without food, as directed by a healthcare professional. While taking the extended-release tablet, part of the tablet may pass into your stool after your body has absorbed the medicine. This is normal and nothing to worry about.

Store the medication at room temperature, away from moisture, heat, and direct sunlight.

Hypoglycemia (especially when used in combination with insulin or insulin secretagogues), Genital yeast infections or urinary tract infections, Increased urination or thirst, Nasopharyngitis (common cold), Headache, Dizziness.

Patients should be monitored regularly for signs of hypoglycemia, especially when Vildagliptin SR + Dapagliflozin is used in combination with insulin or insulin secretagogues. This medication should be used with caution in patients with renal impairment, as dapagliflozin is primarily excreted by the kidneys, and dose adjustments may be necessary to prevent adverse effects Vildagliptin Sr 100 Mg + Dapagliflozin 10 Mg Tablet should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis. Patients should be advised to adhere to a regular meal schedule and monitor blood sugar levels closely while taking this medication.

Product Information: Jalra oral tablets, vildagliptin oral tablets. Novartis Europharm Limited (per EMA), Camberley, United Kingdom, 2015. Product Information: Galvus oral tablets, vildagliptin oral tablets. Novartis Europharm Limited (per EMA), Camberley, United Kingdom, 2016. Scheen AJ, Tan MH, Betteridge DJ, et al. Long-term glycaemic efficacy and weight changes with dapagliflozin versus sitagliptin add-on in inadequately controlled type 2 diabetes on metformin. Product Information: FORXIGA(R) oral tablets, dapagliflozin oral tablets. AstraZeneca Pharmaceuticals LP (per manufacturer), Wilmington, DE, 2021. Dandona P, Mathieu C, Phillip M, et al: Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5(11):864-876.

Vildagliptin inhibits the enzyme DPP-4, which leads to increased levels of active incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones stimulate insulin secretion and inhibit glucagon release in a glucose-dependent manner, thereby improving glycemic control. Dapagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. This mechanism of action promotes the elimination of excess glucose from the body, leading to reduced blood sugar levels.

Antidiabetic